Kiora Pharmaceuticals, Inc.
KPRX
$2.84
$0.1917.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -96.20% | 175.85% | |||
| Gross Profit | 96.20% | -175.85% | |||
| SG&A Expenses | -9.10% | 12.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.89% | -18.00% | |||
| Operating Income | -9.89% | 18.00% | |||
| Income Before Tax | -9.40% | 4.10% | |||
| Income Tax Expenses | -191.14% | -94.04% | |||
| Earnings from Continuing Operations | 1.85% | 48.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.85% | 48.08% | |||
| EBIT | -9.89% | 18.00% | |||
| EBITDA | -9.74% | 17.82% | |||
| EPS Basic | -3.77% | 48.07% | |||
| Normalized Basic EPS | -25.26% | 9.86% | |||
| EPS Diluted | -3.85% | 48.08% | |||
| Normalized Diluted EPS | -25.26% | 9.86% | |||
| Average Basic Shares Outstanding | -5.41% | -0.03% | |||
| Average Diluted Shares Outstanding | -5.41% | -0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||